Imugene (IUGNF)
OTHER OTC:IUGNF
IUGNF Stock Chart & Stats
$0.18
>-$0.01(-3.57%)
At close: 4:00 PM EST
$0.18
>-$0.01(-3.57%)
Day’s Range― - ―
52-Week Range$0.03 - $1.05
Previous CloseN/A
Volume3.00K
Average Volume (3M)16.95K
Market Cap
$37.68M
Enterprise Value$40.87M
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$5.02M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding357,028,170
10 Day Avg. Volume11,247
30 Day Avg. Volume16,948
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue13.02
Enterprise Value/Gross Profit14.66
Enterprise Value/Ebitda-0.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$3.43M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Capital StructureA debt-to-equity ratio of 0.24 and a ~53.9% equity ratio indicate limited financial leverage. This conservative capital structure reduces interest burden and gives management more optionality to fund clinical programs via equity, grants, or partnerships without immediate refinancing stress.
Diverse Clinical-Stage Immuno-Oncology PipelineMultiple distinct clinical and preclinical programs (CF33 oncolytic candidates, PD1-Vaxx, HER-Vaxx) provide 'multiple shots on goal.' This product diversification lowers single-program binary risk and enhances long-term partnership, licensing, or out-licensing opportunities if one or more candidates show positive data.
Free Cash Flow Exceeds Reported Net IncomeA free cash flow to net income ratio >1 suggests that after adjustments, cash generation relative to accounting losses is not entirely negative. While operating cash flow is challenged, this metric indicates pockets of cash discipline or non-cash charges and can signal better near-term ability to fund activities versus peers with purely negative cash conversion.
Bears Say
Steep Revenue DeclineA reported revenue contraction of -338.95% represents a material loss of revenue base or one-off reversals, undermining commercial traction and reducing operating flexibility. For a clinical-stage biotech, this heightens urgency to secure funding or partner deals to sustain programs and preserve credibility with investors.
Persistent Losses And Negative Operating MarginsDeeply negative net margin and negative EBIT/EBITDA show the company is not covering R&D and operating costs from revenue. Structurally, sustained negative margins increase reliance on external financing, dilute shareholder value over time, and raise execution risk for advancing expensive clinical programs.
Weak Operating Cash Flow / Cash GenerationNegative operating cash flow indicates ongoing cash burn from core activities, which is critical for a clinical-stage firm with no product revenue. This structural cash consumption increases dependency on equity raises, grants or licensing deals and materially influences the firm's ability to fund multi-year clinical trials without dilution.
Imugene News
IUGNF FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest stock price was $0.03 and its highest was $1.05 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is $37.68M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Aug 28, 2026 which is in 140 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -$0.091 earnings per share for the quarter, beating the consensus estimate of -$0.239 by $0.148.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imugene have?
Imugene has 357,028,170 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -$0.091 in its last earnings report, beating expectations of -$0.239. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in IUGNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IUGNF Sentiment 76%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.97%
12-Months-Change
Fundamentals
Return on Equity
-134.65%
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Ownership Overview
4.37% Insiders
1.03% Mutual Funds
― Other Institutional Investors
94.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---